Clinical applications of dendritic cell vaccines

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 1, 2000, Pages 20-28

  Morse, Michael A ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Active immunotherapy; Dendritic cells; Tumor antigen; Vaccines

Indexed keywords

CANCER VACCINE; CYTOKINE; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; TUMOR ANTIGEN; VACCINE;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DRUG ADMINISTRATION ROUTE; DRUG INDUCED DISEASE; HUMAN; KIDNEY CARCINOMA; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PARATHYROID CARCINOMA; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; MULTIPLE MYELOMA; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 0034016140     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Roth C, Rochlitz C, Kourilsky P: Immune response against tumors. Adv Immunol (1994) 57:281-351.
2. Darrow T, Slingluff C, Seigler H: The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T-lymphocytes. Evidence for shared tumor antigens. J Immunol (1989) 142:3329-3335.
3. Disis ML, Calenoff E, Mclaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Cheever MA: Existent T-cell and antibody immunity to HER2/neu protein In patients with breast cancer. Cancer Res (1994) 54:16-20.
4. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor specific cytotoxic T-lymphocyte lines. J Exp Med (1995) 181:2109-2117.
5. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J: Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 87:982-990.
6. Van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T: Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 44:634-640.
7. Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T: Precursor frequency analysis of human cytolytic T-lymphocytes directed against autologous melanoma cells. Int J Cancer (1992) 50:289-297.
8. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A: Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer (1994) 58:330-339.
9. Liu Y, Janeway CA: Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T-cells. Proc Natl Acad Sci USA (1992) 89:3845-3849.
10. Morse MA, Lyerly HK: The isolation and culture of human dendritic cells. In: Human Cell Culture, Vol IV Primary Hematopoletic Cells. Koller MF, Palsson BO, Masters JRW (Eds), Kluver Academic Publishers, Dordrecht (1999):171-192.
11. Esche C, Shurin MR, Lotze MT: The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther (1999) 1:72-81.
12. Tarte K, Klein B: Dendritic cell-based vaccine: A promising approach for cancer immunotherapy. Leukemia (1999) 13:653-663.
13. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F: Induction of antigen-specific cytolytic T-cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA (1995) 92:8078-8082. The first study using cultured APCs loaded with tumor amtigens. In vivo immunological responses were observed.
14. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B: Enhancement of cytolytic T-lymphocyte precursor frequency In melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res (1996) 56:2479-2483.
15. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med (1998) 4:328-332. Only study to report intranodal administration of DCs. Clinical responses were documented.
16. Lotze MT, Hellerstedt B, Stolinskl L, Tueting T, Wilson C, Kinzler D, Vu H, Rubin JT, Storkus W, Tahara H, Elder E, Whiteside T: The role of interieukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am (1997) 3:S109-114.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med (1998) 4:321-327.
18. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taldi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med (1996) 2:52-58. The first study to use DCs isolated from peripheral blood for immunization. Clinical and immunological responses were observed.
19. Timmerman JM, Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med (1999) 50:507-529.
20. Reichardt V, Okada C, Benike C, Long G, Engleman E, Blum K, Levy R: Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood (1996) 88:481a.
21. Wen YJ, Ling M, Bailey-Wood R, Lim SH: Idiotype protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res (1998) 4:957-962.
22. Lim SH, Bailey-Wood R: Idiotypic protein-pulsed dendritic cell vaccination In multiple myeloma. Int J Cancer (1999) 83:215-222. Clinical trial of six patients receiving Id-loaded DC immunizations. Immune responses were observed in most patients.
23. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29:371-380. The largest study of DC-based immunotherapy. Included some patients who received peptides alone and peptides loaded onto in vitro cultured DCs.
24. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP: Evaluation of phase I/II clinical trials In prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 36:39-44.
25. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate (1999) 38:73-78.
26. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL: Phase II prostate cancer vaccine trial: report of a study Involving 37 patients with disease recurrence following primary treatment Prostate (1999) 39:54-59.
27. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate (1999) 40:125-129.
28. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP: GM-CSF as a systemic adjuvant In a phase II prostate cancer vaccine trial. Prostate (1999) 39:291-297.
29. Valone FH, Small EJ, Whisenant S, Peshwa M, Strang G, Laus R, Ruegg C, van Schooten W: Immunotherapy of hormone refractory prostate cancer with antigen-pulsed dedritic cells: A Phase I/II study. Proc Am Soc Clin Oncol (1998) 17:Abs 1334.
30. Hinkle A, Gitlitz B, Mulders P, Moldawer N, Tso C, Kaboo R, Beldegrun A, Figlin R: Dendritic cell therapy for metastatic renal cell carcinoma - A translational phase I clinical trial. Proc Am Soc Clin Oncol (1998) 17:Abs 1665.
31. Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thumer M: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer (letter). Lancet (1998) 352:1358.
32. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 5:1331-1338.
33. Schott M, Feldkamp J, Schattenberg D, Seissler J, Scherbaum WA: Dendritic cell immuno-therapy In disseminated parathyroid carcinoma. Lancet (1999) 353:1188-1189.
34. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest (1999) 104:173-180. A carefully controlled study in healthy volunteers demonstrating that a single injection of antigen-loaded DCs is capable of inducing antigen-specific T-cell responses.
35. Steinman RH: The dendritic cell system and Its role in immunogenicity. Ann Rev Immunol (1991) 9:271-296. A comprehensive paper on DCs, a good starting place for a review.
36. Grouard G, Durand I, Filgueira L, Banchereau J, Liu YJ: Dendritic cells capable of stimulating T-cells in germinal centers. Nature (1996) 384:364-367.
37. Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate Into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA (1996) 93:2588-2592.
38. Szabolcs P, Moore MAS, Young JW: Expansion of immunostimulatory dendritic cells among the myelold progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol (1995) 154:5851-5861.
39. Galy A, Travis M, Cen D, Chen B: Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity (1995) 3:459-473.
40. Saunders D, Lucas K, Ismaili J, Wu L, Maraskovsky E, Dunn A, Shortman K: Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte macrophage colony-stimulating factor. J Exp Med (1996) 184:2185-2196.
41. Suss G, Shortman K: A subclass of dendritic cells kills CD4 T-cells via Fas/Fas-ligand-induced apoptosis. J Exp Med (1996) 183:1789-1796.
42. Liu YJ, Grouard G, de Bouteiller O, Banchereau J: Follicular dendritic cells and germinal centers. Int Rev Cytol (1996) 166:139-179. A comprehensive review of follicular DCs.
43. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods (1996) 196:137-151. Describe clinically revelant methods for generating DCs in vitro, including maturation with monocyte conditioned medium.
44. Morse MA, Zhou U, Tedder TF, Lyerty HK, Smith C: Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy. Ann Surg (1997) 226:6-16.
45. Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiani G, Giannl AM: Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol (1995) 23:1463-1471.
46. Gabrilovich DI, Ciemik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol (1996) 170:101-110. Part of a series of papers by these authors that have shown that vascular endothelial growth factor (VEGF) impairs DCs in vivo.
47. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP: Dendritic cells in antitumor Immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol (1996) 170:111-119.
48. Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM, Parmiani G: Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res (1997) 57:5534-5541.
49. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods (1996) 196:121-135.
50. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK: Optimization of the sequence of antigen loading and CD40-ligand-Induced maturation of dendritic cells. Cancer Res (1998) 58:2965-2968. Demonstrates that the optimal sequence of antigen-loading and DC maturation depends on the choice of antigen.
51. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells In flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Wed (1996) 184:1953-1962. Demonstration of the remarkable ability of Fit3L to mobilize DCs into the blood and various tissues of mice.
52. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3 ligand administration Inhibits tumor growth In murine melanoma and lymphoma. Cancer Res (1998) 58:380-383.
53. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3-ligand administration inhibits liver metastases: Role of NK cells. J Immunol (1998) 161:6164-6170.
54. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wlebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cometta K: Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res (1997) 57:3511-3516.
55. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC: Flt3 ligand induces tumor regression and antitumor immune responses In vivo. Nature Med (1997) 3:625-631.
56. Lynch DH: Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses In vivo. Crit Rev Immunol (1998) 18:99-107.
57. Lebsack ME, McKenna HJ, Hoek JA, Hanna R, Feng A, Maraskovsky E, Hayes FA: Safety of Flt3 ligand In healthy volunteers. Stood (1997) 90(10 Suppl 1):Abs 751.
58. Maraskovsky E, Roux E, Teepe M, Brady S, Hoek J, Lebsack M, McKenna HJ: Flt3 ligand increases peripheral blood dendritic cells In healthy volunteers. Blood (1997) 90(10 Suppl 1):Abs 2585.
59. Zitvogel L, Regnault A, Lozler A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med (1998) 4:594-600. Description of the use of a promising cell-free derivative of DCs.
60. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G: Cytotoxic T-cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol (1996) 156:208-217.
61. Nair SK, Snyder D, Rouse BT, Gilboa E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer (1997) 70:706-715.
62. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM: Dendritic cells as carriers for a eytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol (1995) 18:86-94.
63. Wong C, Morse M, Nair SK: Induction of primary, human antigen-specific eytotoxlc T-lymphocytes in vitro using dendritic cells pulssd with peptides. J Immunother (1998) 21:32-40.
64. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T-cells, B7 costimulation, and T-helper cell 1-asssociated cytokines. J Exp Med (1996) 183:87-97.
65. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P: Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res (1996) 56:5672-5677.
66. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA Induce antitumor immunity against central nervous system tumors. J Exp Med(1997) 7:1177-1182.
67. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 184:465-472. Report of a novel method of loading DCs that may have wide-ranging applicabilty.
68. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392:86-89.
69. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ: Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res (1999) 59:3340-3345. This paper demonstrates that the route of administration of DCs is important in the induction of immune responses.
70. Oluwole SF, Fawwaz RA, Engelstad K, Wang TS, Hardy MA: Migration patterns of indium-111 labeled dendritic cells in the rat. Prog Clin Biol Res (1990) 355:247-256.
71. Kuplec-Weglinski JW, Austyn JM, Morris PJ: Migration patterns of dendritic cells In the mouse. J Exp Med (1988) 167:632-645.
72. Possum S: Lymph-borne dendritic leukocytes do not recirculate, but enter the lymph node paracortex to become Interdigitating cells. Scand J Immunol (1988) 27:97-105.
73. Barratt-Boyes SM, Watkins SC, Finn OJ: In vivo migration of dendritic cells differentiated In vitro. J Immunol (1997) 158:4543-4547.
74. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 59:56-58. First paper describing migration of monocyte-derived DCs after intravenous and intradermal administration.
75. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A: Homing of intravenously and intralymphatically injected human dendritic cells generated In vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother (1999) 48:118-122.
76. Shimizu K, Fields RC, Giedlin M, Mule JJ: Systemic administration of interleukln 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA (1999) 96:2268-2273.